Autopsy report · NCT02806960
A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes
Cause of deathOther
“Drug delivery was below target dose due to partial obstruction by aggregated particles.”
Life of this trial
- Registered 1 year 11 months after it had already started.
- Ran for about 2 months before it stopped.
- 12 participants enrolled.
- Results were posted on the registry 5 years 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Conditions
- Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
- Interventions
- Nasal Glucagon
- Participants
- 12
- Sites
- 1
- Countries
- Canada
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.